Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2019 Jun;47(6):2555-2561.
doi: 10.1177/0300060518820412. Epub 2019 May 9.

Effect of montelukast combined with methylprednisolone for the treatment of mycoplasma pneumonia

Hongtu Wu  1 , Xian Ding  1 , Deyu Zhao  2 , Yong Liang  3 , Wei Ji  4
Affiliations
Randomized Controlled Trial

Effect of montelukast combined with methylprednisolone for the treatment of mycoplasma pneumonia

Hongtu Wu et al. J Int Med Res. 2019 Jun.

Abstract

Objective: To study the effect of the leukotriene receptor agonist montelukast combined with methylprednisolone on inflammatory response and peripheral blood lymphocyte subset content in children with mycoplasma pneumonia.

Methods: Seventy-four children were enrolled and randomly divided into a standard treatment group and a montelukast plus methylprednisolone group. Serum levels of inflammatory cytokines and corresponding cytokines of T lymphocyte subsets were measured, and peripheral blood was collected to determine the T cell subset content.

Results: At 3 days and 7 days after treatment, serum MCP-1, PCT, ICAM-1, CXCL8, CRP, IFN-γ, and IL-17 levels and peripheral blood Th1 and Th17 content were significantly decreased in both groups, while serum IL-4 and TGF-β levels and peripheral blood Treg and Th2 content were significantly increased. However, serum MCP-1, PCT, ICAM-1, CXCL8, CRP, IFN-γ, and IL-17 levels and peripheral blood Th1 and Th17 content were significantly lower while serum IL-4 and TGF-β levels and peripheral blood Treg and Th2 content were significantly higher in the montelukast plus methylprednisolone group compared with the control group.

Conclusion: Montelukast combined with methylprednisolone for the treatment of mycoplasma pneumonia can inhibit inflammatory responses and regulate levels of Th1/Th2 and Th17/Treg cells.

Keywords: Mycoplasma pneumonia; children; glucocorticoid; immune response; inflammatory response; montelukast.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Cillóniz C, Torres A, Niederman M, et al. Community-acquired pneumonia related to intracellular pathogens. Intensive Care Med 2016; 42: 1374–1386. - PubMed
    1. Zhang Y, Zhou Y, Li S, et al. The clinical characteristics and predictors of refractory mycoplasma pneumoniae pneumonia in children. PloS One 2016; 11: e0156465. - PMC - PubMed
    1. Gao S, Wang L, Zhu W, et al. Mycoplasma pneumonia infection and asthma: a clinical study. Pak J Med Sci 2015; 31: 548–551. - PMC - PubMed
    1. Gong L, Xu L, Diao M, et al. Clinical effect of treating secondary asthma attacks of children mycoplasma pneumoniae with combined therapy of montelukast and azithromycin. Eur Rev Med Pharmacol Sci 2016; 20: 5256. - PubMed
    1. Zhou H Clinical study of methylprednisolone combined with azithromycin in the treatment of mycoplasma pneumonia in children. China Foreign Medical Treatment 2017; 26:120–122.

Publication types

MeSH terms